# ERMEZA

NDC: 49502-378
Generic name: levothyroxine sodium
Labeler / Manufacturer: Viatris Specialty LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: SOLUTION
Routes: ORAL
Marketing started: 20221214
Marketing ended: 20260731
FDA application: NDA215809

## Active ingredients

- LEVOTHYROXINE SODIUM: 30 ug/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"49502-378"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=49502-378
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ceeadb4-18be-46c7-9204-68b4edfbb96b